These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1960870)

  • 1. [Aldose reductase inhibitors].
    Yoneta T; Tagashira E
    Nihon Rinsho; 1991 Sep; 49(9):2017-23. PubMed ID: 1960870
    [No Abstract]   [Full Text] [Related]  

  • 2. The distribution of aldose reductase and aldehyde reductase II in different regions of bovine lens.
    Liu S; Das B; Srivastava SK
    Lens Eye Toxic Res; 1989; 6(3):415-30. PubMed ID: 2518623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
    Kador PF; Kinoshita JH; Sharpless NE
    J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
    [No Abstract]   [Full Text] [Related]  

  • 4. Aldose reductase in diabetic cataracts.
    Kinoshita JH; Kador P; Catiles M
    JAMA; 1981 Jul; 246(3):257-61. PubMed ID: 6787220
    [No Abstract]   [Full Text] [Related]  

  • 5. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy.
    Dyck PJ; Zimmerman BR; Vilen TH; Minnerath SR; Karnes JL; Yao JK; Poduslo JF
    N Engl J Med; 1988 Sep; 319(9):542-8. PubMed ID: 3136330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated and unactivated forms of human erythrocyte aldose reductase.
    Srivastava SK; Hair GA; Das B
    Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7222-6. PubMed ID: 3933003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorbitol pathway activity and utilization of polyols in astroglia-rich primary cultures.
    Wiesinger H; Thiess U; Hamprecht B
    Glia; 1990; 3(4):277-82. PubMed ID: 2144507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of aldose reductase inhibitors.
    Zimmerman BR
    Diabetes Care; 1987; 10(1):123-5. PubMed ID: 3105984
    [No Abstract]   [Full Text] [Related]  

  • 10. Aldose reductase and the etiology of diabetic cataracts.
    Varma SD
    Curr Top Eye Res; 1980; 3():91-155. PubMed ID: 6807610
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase inhibitors and diabetic complications.
    Tomlinson DR; Willars GB; Carrington AL
    Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
    Madhu SV; Verma NP; Goel A; Kapoor VK
    J Assoc Physicians India; 1992 Oct; 40(10):679-81. PubMed ID: 1307356
    [No Abstract]   [Full Text] [Related]  

  • 15. Oxidized aldose reductase: in vivo factor not in vitro artifact.
    Grimshaw CE; Lai CJ
    Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the polyol pathway in diabetes mellitus.
    Collier A; Small M
    Br J Hosp Med; 1991 Jan; 45(1):38-40. PubMed ID: 1901236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sorbinil on the pathophysiology of diabetic complications. Proceedings of a symposium. Dorado, Puerto Rico, May 30-June 2, 1985.
    Metabolism; 1986 Apr; 35(4 Suppl 1):1-121. PubMed ID: 3083196
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
    Yabe-Nishimura C
    Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity.
    Kolb NS; Hunsaker LA; Vander Jagt DL
    Mol Pharmacol; 1994 Apr; 45(4):797-801. PubMed ID: 8183257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.